Stock listing

Stuttgart:PYPB IXICO PLC Aktie

German listing (Stuttgart) of IXICO PLC · home listing LSE:IXI

Follow IXICO PLC into a list and get an email when it puts out news.

Home listing price · LSE:IXI

13.00p GBX (pence) +0.25 (+2.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, LSE:IXI

Past year +23.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
12.50p – 13.35p GBX (pence)Nov 20, 2026
Volume
23,918 sharesNov 20, 2026
Market cap
£28.47M GBPAt the close on Nov 20, 2026 · price × 219.0M shares outstanding
52-week range
6.26p – 17.00p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
£18,221 GBPMedian day 30,172 shares · 3 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
IXICO PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
LSE:IXI · Home13.00p GBX (pence)+0.25 (+2.0%)23,91813.00p13.35p12.50p12.75pClose on Nov 20, 2026
OTC:PHYOF$0.07 USD0.00 (0.0%)—$0.07$0.07$0.07$0.07Close on Nov 6, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:IXI · GBX (pence), adjusted for splits

DayCloseChange%OpenHighLowVolume
13.00p+0.25+2.0%13.00p13.35p12.50p23,918
12.75p0.000.0%12.75p13.00p12.50p107,957
12.75p0.000.0%12.75p13.30p12.57p148,370
12.75p0.000.0%12.75p13.00p12.50p2,216
12.75p-0.25-1.9%13.00p13.13p12.50p152,188
13.00p0.000.0%13.00p13.10p12.68p43,337
13.00p0.000.0%13.00p13.17p12.50p97,883
13.00p0.000.0%13.00p13.25p13.00p2,631
13.00p0.000.0%13.00p13.25p12.50p44,655
13.00p-1.50-10.3%14.25p14.44p12.26p308,569
14.50p-1.00-6.5%15.50p16.00p14.25p334,713
15.50p0.000.0%15.50p16.00p15.00p103,021
15.50p+1.50+10.7%15.75p17.00p15.00p751,620
14.00p+2.25+19.1%12.25p16.50p12.00p2,649,879
11.75p0.000.0%11.75p12.00p11.55p92,889
11.75p0.000.0%11.75p12.33p11.60p186,557
11.75p0.000.0%11.75p12.50p11.50p326,352
11.75p+1.50+14.6%10.25p12.50p9.50p693,198
10.25p+0.25+2.5%10.00p11.00p9.50p18,738
10.00p+0.25+2.6%9.50p11.00p9.50p287,601
9.75p+1.25+14.7%9.25p10.00p8.50p780,801
8.50p0.000.0%8.50p9.00p8.00p20,815
8.50p+0.75+9.7%8.25p10.00p8.00p1,336,670
7.75p0.000.0%7.75p8.50p7.00p3,307
7.75p0.000.0%7.75p8.50p7.00p58,391
7.75p0.000.0%7.75p8.50p7.00p172
7.75p0.000.0%7.75p8.25p7.55p5,999
7.75p0.000.0%7.75p8.50p7.55p42,414
7.75p0.000.0%7.75p8.50p7.455p17,645
7.75p0.000.0%7.75p8.199p7.455p8,415
7.75p-0.25-3.1%7.75p8.50p7.455p7,685
8.00p0.000.0%8.00p8.50p7.65p137,816
8.00p0.000.0%8.00p8.50p7.65p2,302
8.00p+0.50+6.7%7.50p8.50p7.00p165,115
7.50p0.000.0%7.50p8.00p7.00p10,788
7.50p0.000.0%7.50p7.68p7.50p1,000
7.50p0.000.0%7.50p7.50p7.50p0
7.50p0.000.0%7.50p7.80p7.255p166,218
7.50p0.000.0%7.50p8.00p7.00p15,383
7.50p0.000.0%7.50p8.00p7.50p12,529
7.50p+0.10+1.4%7.399p7.75p7.399p106,916
7.40p-0.10-1.3%7.25p7.50p7.075p235,066
7.50p0.000.0%7.50p8.00p7.11p95,108
7.50p0.000.0%7.50p7.50p7.15p143
7.50p0.000.0%7.50p8.00p7.15p10,914
7.50p0.000.0%7.50p8.00p7.00p332
7.50p0.000.0%7.50p7.50p7.15p59,282
7.50p0.000.0%7.50p8.00p7.00p17,227
7.50p0.000.0%7.50p8.00p7.15p1,981
7.50p0.000.0%7.50p8.00p7.00p299,096
7.50p0.000.0%7.50p8.00p7.00p10,741
7.50p0.000.0%7.50p8.00p7.00p30,987
7.50p0.000.0%7.50p7.575p7.50p1,716
7.50p0.000.0%7.50p8.00p7.00p7,403
7.50p0.000.0%7.50p8.00p7.166p12,823
7.50p0.000.0%7.50p8.00p7.33p57,826
7.50p0.000.0%7.50p7.75p7.50p20,000
7.50p-0.25-3.2%7.75p8.00p7.00p70,164
7.75p0.000.0%7.75p7.75p7.75p0
7.75p0.000.0%7.75p7.75p7.556p60,000
7.75p0.000.0%7.75p7.75p7.556p8,219
7.75p0.000.0%7.75p7.75p7.75p0
7.75p+0.25+3.3%7.69p8.50p7.69p30,172
7.50p0.000.0%7.50p8.00p7.30p14,386
7.50p0.000.0%7.50p8.00p7.00p1,669

Splits

1 split · LSE:IXI · every price before a split is adjusted for it

DayRatioWhat
1-for-50Consolidation
Ticker
Stuttgart:PYPB
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Stuttgart
Currency
EUR

What changed lately

Latest news

IXI Platform & Collaborations Update

Nov 19, 2026

Closed 13.00p (+2.0%) on Nov 20, 2026

New Alzheimer's AI Tool

Nov 17, 2026

Closed 12.75p (0.0%) on Nov 17, 2026

£2.7m clinical phase 3 contract win

Nov 2, 2026

Closed 14.00p (+19.1%) on Nov 2, 2026

Alzheimer's contract wins

Oct 22, 2026

Closed 9.75p (+14.7%) on Oct 22, 2026

Trading Update

Oct 20, 2026

Closed 8.50p (+9.7%) on Oct 20, 2026

HD Industry Update

Jul 13, 2026

Closed 8.25p (-10.8%) on Jul 13, 2026

Exercise of Options

Jun 19, 2026

Closed 8.65p (0.0%) on Jun 19, 2026

Scientific advisors & partners update

Jun 8, 2026

Closed 8.65p (0.0%) on Jun 8, 2026

All IXICO PLC news

IXICO PLC on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
27 in the last 12 months · 343 in all · newest Nov 19, 2026 · oldest 1999
Calls
14 calls with a replay · 14 with a transcript · latest May 19, 2026
Decks
11 decks · latest Apr 1, 2026

Where IXICO PLC is listed

ListingExchangeCountryCurrency
LSE:IXI · Home listingLSEUnited KingdomGBX
OTC:PHYOFOTCUnited StatesUSD
LS Exchange:A2N478LS ExchangeGermanyEUR
Lang & Schwarz:A2N478Lang & SchwarzGermanyEUR
Frankfurt:PYPBFrankfurtGermanyEUR
Stuttgart:PYPB · This pageStuttgartGermanyEUR

Valuation

EV/sales 4.2× against a median of 0.8×: 9th lowest of 11 Diagnostics & research services companies shown. Statements: Year to Sep 30, 2025 · balance Mar 31, 2026 · price Nov 20, 2026

Enterprise value
£27.35M GBP
P/E
Loss
EV/sales
4.2×
EV/EBITDA
Negative EBITDA
Price/book
2.7×
Gross margin
44.5%
Operating margin
−38.7%
Net margin
−25.3%
Debt to equity
0.1×
Beta
No index for this market yet

Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
IXICO PLC · LSE:IXIUS$37.27MUS$35.81Mn/a4.2×n/a2.7×−25.3%0.1×n/a
Osang Healthcare Co. Ltd. · KRX:036220US$42.35MUS$24.18Mn/a0.3×n/a0.2×−8.8%0.1×n/a
ABL Diagnostics SA · EURONEXT:ABLDUS$41.28MUS$42.32M38.1×5.5×42.8×5.3×14.2%0.3×n/a
hVIVO plc · LSE:HVOUS$41.01MUS$42.24Mn/a0.7×7.5×1.0×−12.8%0.4×n/a
Harvard Bioscience, Inc. · NASDAQ:HBIOUS$39.60MUS$71.90Mn/a0.8×28.4×7.8×−13.2%7.3×1.34
CytoGen, Inc. · KRX:217330US$38.59MUS$31.67Mn/a1.6×n/a1.6×−38.5%0.4×n/a
HUMASIS Co., Ltd. · KRX:205470US$37.49M−US$89.15Mn/a−3.8×n/a0.2×−49.2%0.0×n/a
Mabion SA · GPW:MABUS$35.44MUS$42.01Mn/a9.7×n/a6.0×−321.4%1.3×n/a
Trajan Group Holdings Ltd · ASX:TRJUS$34.94MUS$64.98Mn/a0.6×7.6×0.5×−0.4%0.6×n/a
Novacyt SAS · EURONEXT:ALNOVUS$33.87MUS$35.59Mn/a0.8×n/a1.4×−102.4%0.6×n/a
Rapid Micro Biosystems, Inc. · NASDAQ:RPIDUS$33.56MUS$46.06Mn/a1.3×n/a3.8×−138.2%2.2×1.41
Median of the othersUS$38.04MUS$42.12M38.1×0.8×18.0×1.5×−25.9%0.5×1.38

Forecasts

Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
26.00 GBX · Analysts' mean
EPS, year to Sep 2026
-0.014 · 1 analyst
Revenue, year to Sep 2026
8M · 1 analyst

Team and board

Officers

OfficerRole
Bram GoordenChief Executive Officer
Grant NashChief Financial Officer, Chief Operating Officer and Company Secretary
James ChandlerChief Business Officer
Tanya VoloshenChief Commercial Officer

Board

DirectorRole
Mark WarneNon-executive chair
Bram GoordenChief Executive Officer
Dipti AminNon-executive Director
Grant NashChief Financial Officer, Chief Operating Officer and Company Secretary
Kate RogersNon-Executive Director and Senior Independent Director

Events

Calls

CallWhenStatus
IXICO (LSE:IXI) Q2 2026 Earnings CallTue, May 19, 2026 · 11:30 AM ETReplay
IXICO (LSE:IXI) Q4 2025 Earnings CallTue, Dec 09, 2025 · 11:30 AM ETReplay
IXICO (LSE:IXI) — Capital Markets DayThu, Oct 30, 2025 · 10:00 AM ETReplay
IXICO (LSE:IXI) — Interim results for the six months ended 31 March 2025Tue, May 20, 2025 · 11:30 AM ETReplay
IXICO (LSE:IXI) — Full Year ResultsThu, Dec 05, 2024 · 11:30 AM ETReplay
IXICO (LSE:IXI) — Investor PresentationTue, May 21, 2024 · 11:30 AM ETReplay
IXICO (LSE:IXI) — Investor PresentationTue, Dec 05, 2023 · 11:30 AM ETReplay
IXICO (LSE:IXI) — Investor PresentationTue, May 23, 2023 · 11:30 AM ETReplay
IXICO (LSE:IXI) — Full Year ResultsWed, Dec 07, 2022 · 11:30 AM ETReplay
IXICO (LSE:IXI) — Interim ResultsTue, May 24, 2022 · 11:30 AM ETReplay
All 14 calls
CallWhenStatus
IXICO (LSE:IXI) — Final Results for the year ended 30 September 2021Tue, Dec 07, 2021 · 11:30 AM ETReplay
IXICO (LSE:IXI) — Half-year results for the six months ended 31 March 2021Tue, May 25, 2021 · 10:30 AM ETReplay
IXICO (LSE:IXI) — Final Results for the year ended 30 September 2020Wed, Dec 02, 2020 · 10:30 AM ETReplay
IXICO (LSE:IXI) — Investor PresentationTue, Aug 25, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q2 2025May 20, 2025+35.6%
Q4 2024Dec 20, 2024−2.1%
Quarter to Dec 31, 2023Jan 25, 2024 · Before open−18.0%
Q4 2023Dec 5, 2023 · After close−3.5%
Quarter to Jun 30, 2023Aug 30, 20230.0%
Q2 2023May 23, 2023 · Before open−11.4%
Quarter to Dec 31, 2022Mar 1, 20230.0%
Q4 2022Dec 7, 2022 · Before open−9.4%
Q3 2022Aug 31, 2022+12.7%
Q2 2022May 24, 2022−9.4%
All 14 quarters
QuarterResultsShare move
Q1 2022Mar 2, 20220.0%
Q4 2021Dec 7, 2021+23.0%
Q3 2021Sep 1, 2021+0.7%
Q2 2021May 25, 2021+6.0%

Open Events

Decks

DeckKindSlidesDate
Investor Day (April 2026)Investor day20 slidesApr 1, 2026
Ixico Plc Ord New — FY2025 Earnings PresentationEarnings20 slidesDec 9, 2025
Investor Day (October 2025)Investor day53 slidesOct 30, 2025
H1 2025 Earnings PresentationEarnings20 slidesMay 2025
FY2024 Earnings PresentationEarnings24 slidesDecember 2024
FY2023 Earnings PresentationEarnings35 slidesDec 5, 2023
H1 2023 Earnings PresentationEarnings30 slidesMay 23, 2023
FY2022 Earnings PresentationEarnings20 slidesDec 7, 2022
FY2021 Earnings PresentationEarnings19 slidesDec 7, 2021
FY2020 Earnings PresentationEarnings20 slidesDec 2, 2020
All 11 decks
DeckKindSlidesDate
FY2019 Earnings PresentationEarnings30 slidesDec 4, 2019

Open Decks

Financings

RaiseDate
Private placement of new ordinary shares
Update: private placement
Apr 16, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in GBP

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue6.53M5.77M6.67M8.64M9.19M9.53M7.56M5.39M4.10M3.27M
Cost of revenue3.63M3.06M3.40M3.87M3.66M3.62M2.62M2.22M1.79M1.68M
Gross profit2.91M2.71M3.27M4.77M5.53M5.91M4.94M3.17M2.31M1.59M
Research and development1.33M1.50M925.0K1.22M1.24M1.31M1.00M1.03M1.26M1.58M
Selling, general and administrative2.49M2.91M2.34M2.58M2.44M2.82M2.74M2.45M2.31M2.16M
Operating income-2.53M-2.15M-1.44M908.0K1.12M236.0K364.0K-797.0K-1.43M-2.16M
Depreciation and amortization411.0K475.0K625.0K639.0K609.0K438.0K112.0K152.0K192.0K347.0K
EBITDA-2.12M-1.68M-812.0K1.55M1.73M674.0K476.0K-645.0K-1.24M-1.82M
Interest expense16.0K25.0K29.0K33.0K22.0K18.0K25.0K000
Income before tax-2.45M-2.09M-1.36M885.0K1.10M696.0K366.0K-793.0K-1.91M-2.87M
Income tax-798.0K-93.0K-183.0K-147.0K-415.0K-256.0K-66.0K-125.0K-375.0K-750.0K
Net income-1.65M-2.00M-1.18M1.03M1.51M952.0K432.0K-668.0K-1.54M-2.12M
Earnings per share, basic-0.02-0.04-0.020.020.030.020.01-0.02-0.06-0.09

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.54M1.79M4.03M5.77M6.68M7.95M7.26M7.86M2.41M3.12M
Receivables2.70M2.21M945.0K3.00M3.29M2.76M1.93M2.11M1.25M1.01M
Inventory111111
Current assets6.23M4.49M6.29M9.25M10.5M10.3M10.1M10.2M4.32M5.04M
Property, plant and equipment817.0K1.08M1.01M316.0K77.0K60.0K88.0K
Total assets13.8M11.2M13.0M14.7M14.3M12.1M10.7M10.3M4.51M5.68M
Accounts payable75.0K83.0K86.0K254.0K734.0K176.0K597.0K339.0K270.0K216.0K
Current liabilities2.06M1.57M1.28M1.74M2.15M2.67M2.78M3.01M1.80M1.49M
Total debt179.0K314.0K387.0K516.0K597.0K213.0K
Total liabilities2.10M1.72M1.56M2.16M2.78M2.98M2.78M3.01M1.82M1.60M
Shareholders' equity11.7M9.46M11.4M12.5M11.5M9.12M7.92M7.33M2.69M4.08M
Shares outstanding89.5M48.3M48.3M50.8M50.4M47.5M46.8M33.8M26.9M24.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-883.0K-1.73M302.0K1.43M614.0K1.94M-130.0K355.0K-644.0K-1.53M
Capital spending-51.0K-471.0K-1.96M-2.25M-2.15M-1.14M-217.0K-60.0K-21.0K-24.0K
Free cash flow-934.0K-2.20M-1.66M-815.0K-1.54M795.0K-347.0K295.0K-665.0K-1.56M
Cash from investing-870.0K-377.0K-1.86M-2.25M-2.15M-1.14M-513.0K-71.0K-49.0K75.0K
Cash from financing3.50M-134.0K-156.0K-114.0K270.0K-112.0K48.0K5.16M5.16M2.71M
Share buybacks314.0K65.0K48.0K5.50M2.71M
Change in cash1.75M-2.24M-1.74M-915.0K-1.26M681.0K-597.0K5.45M-706.0K1.19M

Open Financials

Cap table

Built by 6ix from IXICO PLC’s releases

Common shares
218,974,282
Fully diluted
218,974,282

Fully diluted

LineShares
Common shares218,974,282

Share count over time

CountShares
Nov 22, 2026218,974,282

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Bram GoordenChief Executive Officer · Since at least Oct 22, 2026
Dipti AminNon-executive Director · Since at least Mar 31, 2026
Grant NashChief Financial Officer, Chief Operating Officer and Company Secretary · Since at least Oct 29, 2026
James ChandlerChief Business Officer · Since at least Apr 16, 2026
Kate RogersNon-Executive Director and Senior Independent Director · Since at least Jan 23, 2026
Mark WarneNon-executive chair · Since at least Mar 31, 2026
Tanya VoloshenChief Commercial Officer · Since at least Feb 5, 2026

Open People

Log in to ask 6ix AI your own questions about IXICO PLC.